---
title: 'Head of Sales, Rare Disease at REGENXBIO'
canonical: 'https://feeny.ai/job/head-of-sales-rare-disease-regenxbio-remote-qhp7fgpvfvzm'
type: 'job'
last_seen: '2026-11-02'
---

# Head of Sales, Rare Disease at REGENXBIO

- **Company:** REGENXBIO
- **Location:** Remote
- **Employment:** full-time
- **Work type:** remote
- **Posted:** 2026-09-29
- **Last confirmed live:** 2026-11-02
- **Apply:** https://jobs.lever.co/regenxbio/1b4912d4-dbd6-4f8c-90c3-7275d8c3134f

## Job description

Since our founding in 2009, REGENXBIO has pioneered what’s possible in gene therapy. Today, we are advancing a pipeline of gene therapies designed to improve the lives of patients facing serious rare and retinal diseases and preparing to bring innovative new medicines to patients. Our work is fueled by purpose and urgency because every day matters to patients and their families. At REGENXBIO, you’ll find meaningful opportunities to grow, collaborate, and contribute to the advancement of potentially transformative gene therapies. Together, our talented team is working to make a meaningful difference for patients and their families. What we do matters.

The opportunity As Head of Field Strategy, Operations & Excellence (Head of Sales), you will oversee REGENXBIO’s commercial field strategy and execution, drive revenue growth, and ensure alignment of the commercial field organization with the company’s overall business objectives. You’ll set the vision for the field organization, define field and sales processes, and lead the team to achieve ambitious growth targets. In this role you’ll help shape and translate brand strategy and the GTM plan into field execution through close partnership with marketing, market access, medical affairs, commercial enablement and training, and instill a high-performance, highly compliant, patient-centric culture suited to rare disease communities, where every interaction and every patient matters. As the leader of the field organization, you will lead and develop Market Development Directors, Patient Engagement teams, Key Account Managers, and other key field teams, while serving as a member of the Rare Disease Leadership Team.

## What you'll be doing

- Develop and implement a comprehensive national field strategy aligned with franchise priorities, launch plans, and commercial objectives.
- Deliver national and regional sales performance, maximizing the success of the lead asset in DMD market. Set objectives that drive patient access, demand, revenue generation and growth in line with forecast.
- Lead, coach, and develop a high-performing field organization, including regional sales leaders, Key Account Managers, market development roles, and patient engagement roles, focused on DMD providers, institutions, clinics, patients & caregivers. Includes:
- Set clear responsibilities and performance expectations, provide regular feedback, and address performance gaps.
- Develop individual growth plans, leadership bench strength, and succession plans while creating an inclusive culture that values diverse experience and perspectives.
- Lead field launch readiness, including territory design, deployment, targeting, account prioritization, training, and execution planning. Establish readiness milestones and address gaps with cross-functional partners.
- Drive sales force effectiveness through performance management, field KPIs, incentive compensation, analytics, and CRM utilization.
- Partner with Commercial Operations, People, and Finance groups to establish effective incentive compensation plans, field KPIs, business reviews, and recognition programs.
- Partner closely with Brand Marketing, Market Access, Medical Affairs, and other cross-functional teams to translate strategy into exceptional field execution, maintaining appropriate separation of commercial and medical responsibilities.
- Lead and develop Patient Services capabilities, ensuring effective patient access, onboarding, support, education, and coordination with internal and external stakeholders. Work closely with Market Access to identify and help resolve barriers involving payer coverage, prior authorization, reimbursement, treatment-center readiness, and patient onboarding.
- Build strong relationships with key opinion leaders, treating institutions, and professional communities.
- Contribute to portfolio strategy, business planning, forecasting, and resource allocation as a member of the Rare Disease Leadership Team.
- Analyze market dynamics, customer feedback, and field performance to optimize execution, inform strategy and optimize results.
- Champion a culture of compliance, accountability, and patient-centricity across the organization.
- Work closely with other executive and senior leadership teams to align field operations with marketing, finance, IT, operations & enablement, and other key business functions.
- Ability to travel ~50-75% as required.
- It is imperative that REGENXBIO employees embody our core values by working collaboratively, building strong relationships and using clear communication to meet shared objectives.

Why should you apply? By joining REGENXBIO, you will have the opportunity to be a part of a growing company, with an incredible team, who is passionate about developing novel AAV gene therapies for patients in need. We offer a comprehensive and competitive benefit & compensation package which includes market-competitive salaries, an annual bonus program, education assistance, retirement plan with employer match, stock options at all levels, summer hours and more! The estimated compensation range for this role is $262,000 to $373,000 annually. The actual salary offered to the final candidate depends on a number of factors such as relevant work experience, skills, education, and years of experience. In addition, professional development is important to us.  By joining our team, you’ll have the opportunity to be exposed to challenging projects and have access to development resources to help you grow personally and professionally.

## About REGENXBIO

## Company Overview
- **One-liner**: REGENXBIO is a clinical-stage biotechnology company developing one-time gene therapies for rare and retinal diseases using its proprietary AAV vector platform.
- **Entity Type**: Public (NASDAQ: RGNX)
- **Headquarters**: Rockville, Maryland, United States
- **Founded**: 2008 (founded as a company; operations began in 2009)
- **Founders**: Not publicly listed as individual founders; the company was spun out from the gene therapy research of the University of Pennsylvania and licensed its NAV Technology Platform from the university.

## Core Business
- **Primary industry**: Biotechnology – Gene Therapy (AAV-based)
- **Target customers**: B2B (pharma partners like AbbVie, Nippon Shinyaku) and B2G (regulatory agencies, clinical trial sites); ultimate customers are patients with rare and retinal diseases (Duchenne muscular dystrophy, MPS I, MPS II, wet AMD, diabetic retinopathy).
- **Mission or purpose statement**: “To improve lives through the curative potential of gene therapy.” [regenxbio.com](https://www.regenxbio.com/culture-careers/)

## Products & Services
- **NAV® Technology Platform**: Proprietary AAV vector gene delivery platform (including AAV8 and AAV9) used for internal programs and licensed to partners (e.g., Novartis for ZOLGENSMA®).
- **ABBV-RGX-314** (in collaboration with AbbVie): Investigational one-time gene therapy for wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR). In pivotal clinical trials.
- **RGX-202** (Duchenne muscular dystrophy): Phase I/II/III AFFINITY DUCHENNE® trial; pivotal phase expected to support BLA submission in 2026 using accelerated approval pathway. [ir.regenxbio.com](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa)
- **RGX-121** (MPS II – Hunter syndrome): In partnership with Nippon Shinyaku; late-stage development.
- **RGX-111** (MPS I – Hurler syndrome): In partnership with Nippon Shinyaku; clinical development.
- **Manufacturing**: In-house cGMP production facility (REGENXBIO Manufacturing Innovation Center – RMIC) in Rockville, MD, operational since mid-2022.

## Market Standing
- **Valuation/Market Cap**: $447.8 million (as of recent data). [linkedin.com](https://linkedin.com/company/regenx)
- **Key Metric**: Annual Revenue $170.4 million (primarily from license and collaboration revenue). [linkedin.com](https://linkedin.com/company/regenx)
- **Notable Investors/Partners**:
    - AbbVie (collaboration for ABBV-RGX-314)
    - Nippon Shinyaku (partnerships for RGX-121 and RGX-111)
    - Novartis (licensee for ZOLGENSMA® using NAV vectors)
- **Growth Signals**:
    - Headcount: 296 employees (+1.3% YoY). [linkedin.com](https://linkedin.com/company/regenx)
    - BLA submission for RGX-202 targeted for 2026.
    - RMIC facility operational since 2022, enabling scalable clinical and commercial manufacturing.
    - Scholarly output: 160 works, 7,337 citations, field-weighted citation impact of 2.6 (highly influential). [linkedin.com](https://linkedin.com/company/regenx)

## Competitive Advantages
- **Proprietary NAV Technology Platform**: Exclusive rights to a large portfolio of AAV vectors (including AAV8 and AAV9), the foundation for multiple approved and investigational gene therapies. [ir.regenxbio.com](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa)
- **End-to-end capabilities**: Integrated in-house R&D, preclinical development, clinical development, and cGMP manufacturing.
- **Proven platform**: Thousands of patients have been treated with AAV vectors from the NAV platform (including via Novartis’ ZOLGENSMA®).
- **Late-stage pipeline**: Multiple programs in pivotal or near-pivotal trials (RGX-202, ABBV-RGX-314) with clear regulatory pathways.

## Strategic Focus
- **Near-term**: Advance RGX-202 toward BLA submission in 2026; continue pivotal trials for ABBV-RGX-314 in wet AMD and diabetic retinopathy.
- **Long-term**: Expand pipeline in retinal, neuromuscular, and neurodegenerative diseases; leverage RMIC for commercial-scale manufacturing; deepen partnerships with AbbVie and Nippon Shinyaku.
- **Platform expansion**: Ongoing research to expand NAV vector capabilities and develop new AAV-based therapies.

## Why Work Here
- **Mission-driven culture**: “Patient-focused, driven by results, fosters collaboration.” Core values emphasize accountability, innovation, and serving patients with limited therapeutic options. [regenxbio.com](https://www.regenxbio.com/culture-careers/)
- **Impactful work**: Opportunity to work on one-time gene therapies that could fundamentally alter the course of devastating diseases.
- **Growth & stability**: Public company with late-stage pipeline, strong partnerships, and a clear path to commercialization.
- **Location & facilities**: Headquarters in Rockville, MD, with a state-of-the-art cGMP manufacturing facility (RMIC) on site.
- **Work policy**: Not explicitly stated as remote/hybrid; positions appear to be on-site (based on job listings in Rockville and field-based Medical Science Liaison roles).
- **Perks**: Comprehensive and competitive benefits for employees and families. [regenxbio.com](https://www.regenxbio.com/culture-careers/)
- **Engineering & science culture**: High scholarly output and citation impact; emphasis on cross-functional collaboration between research, manufacturing, and clinical teams.
- **Recruitment note**: REGENXBIO warns of fraudulent job offers; all applications go through their official Lever portal. [regenxbio.com](https://www.regenxbio.com/culture-careers/)

## Sources
1. [regenxbio.com – Culture & Careers](https://www.regenxbio.com/culture-careers/)
2. [linkedin.com – REGENXBIO company page](https://linkedin.com/company/regenx)
3. [ir.regenxbio.com – 10-K Filing (Business Overview)](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa)
4. [ir.regenxbio.com – Investor Overview](https://ir.regenxbio.com/investor-overview)
5. [jobs.lever.co – REGENXBIO careers](https://jobs.lever.co/regenxbio)

## Other roles at REGENXBIO

- [Lead Integration Developer](https://feeny.ai/job/lead-integration-developer-regenxbio-rockville-x52a6y2n5b0w) — Rockville, MD
- [VP, Global Rare Disease Franchise](https://feeny.ai/job/vp-global-rare-disease-franchise-regenxbio-remote-zw2996mdrwy4)
- [Vice President, Information Technology](https://feeny.ai/job/vice-president-information-technology-regenxbio-rockville-ekqdx4dtve6s) — Rockville, MD
- [People Intern](https://feeny.ai/job/people-intern-regenxbio-rockville-mq2tm3vcjxe7) — Rockville, MD
- [Associate Director, Regulatory Affairs](https://feeny.ai/job/associate-director-regulatory-affairs-regenxbio-rockville-1grfyr3vz4sy) — Rockville, MD
- [Associate Director, People Business Partner](https://feeny.ai/job/associate-director-people-business-partner-regenxbio-rockville-fmx3gbzx681y) — Rockville, MD
- [Director, Commercial Data, Advanced Analytics & Forecasting](https://feeny.ai/job/director-commercial-data-advanced-analytics-forecasting-regenxbio-remote-88y6fvc5kv5j)
- [Associate Director, Rare Disease Product Marketing](https://feeny.ai/job/associate-director-rare-disease-product-marketing-regenxbio-rockville-r2p05phcvmx8) — Rockville, MD
- [Senior Director, Global Program Development Lead - DMD/Neuromuscular](https://feeny.ai/job/senior-director-global-program-development-lead-dmd-neuromuscular-regenxbio-xbereeg0zrc8) — Rockville, MD
- [Senior Director/Director, Medical Science Liaisons (Neuromuscular/DMD)](https://feeny.ai/job/senior-director-director-medical-science-liaisons-neuromuscular-dmd-regenxbio-aeca83gb75e2)